Effect of Growth Hormone Protocols in Poor Responders Undergoing IVF

Comparison of the Effect of Two Different Protocols of Growth Hormone Administration as Co-treatment on Days 2 and 21 of Menstruation in Poor Responders Undergoing IVF Cycle

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250307064957N1

Enrollment

Registered

2025-05-04

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility with Poor Ovarian Response. Female infertility

Interventions

Intervention 1: Intervention group 1: Patients will undergo long stop protocol and receive 4 units of growth hormone daily from day 21 of the previous cycle until the day of human chorionic gonadotrop

Eligibility

Sex/Gender

Female

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Infertile women with poor ovarian response undergoing IVF cycle based on Bologna criteria Age above 40 years

Exclusion criteria

Exclusion criteria: Normal responders High responders Single ovary Endometriosis and polycystic ovary syndrome Male factor infertility Endocrine disorders (thyroid disorders and hyperprolactinemia) History of malignancy, diabetes, hypertension, thrombocytopenia History of recurrent miscarriages Tubal problems and uterine structure abnormalities (leiomyoma and adenomyosis) Follicle-stimulating hormone (FSH) higher than 15 Body mass index greater than or equal to 30 kg/m²

Design outcomes

Primary

Measure	Time frame
Number of retrieved oocytes. Timepoint: At the time of oocyte retrieval following human chorionic gonadotropin injection. Method of measurement: By counting during oocyte retrieval procedure.	—

Secondary

Measure	Time frame
Number of M II oocytes. Timepoint: At the time of oocyte retrieval following human chorionic gonadotropin injection. Method of measurement: By assessment of oocytes during oocyte retrieval procedure.;Number of embryos. Timepoint: After in vitro fertilization. Method of measurement: By counting the number of embryos obtained from IVF.;Embryo quality. Timepoint: After in vitro fertilization. Method of measurement: By assessment of IVF embryo quality according to standard criteria.;Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: By blood test - beta human chorionic gonadotropin titration.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: By transvaginal ultrasound - observation of sac and embryo with heartbeat.;Ongoing pregnancy. Timepoint: Week twelve of pregnancy. Method of measurement: By transvaginal ultrasound - continuation of pregnancy until week 12.	—

Measure

Time frame

Number of M II oocytes. Timepoint: At the time of oocyte retrieval following human chorionic gonadotropin injection. Method of measurement: By assessment of oocytes during oocyte retrieval procedure.;Number of embryos. Timepoint: After in vitro fertilization. Method of measurement: By counting the number of embryos obtained from IVF.;Embryo quality. Timepoint: After in vitro fertilization. Method of measurement: By assessment of IVF embryo quality according to standard criteria.;Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: By blood test - beta human chorionic gonadotropin titration.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: By transvaginal ultrasound - observation of sac and embryo with heartbeat.;Ongoing pregnancy. Timepoint: Week twelve of pregnancy. Method of measurement: By transvaginal ultrasound - continuation of pregnancy until week 12.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Rezazadeh

Ardabil University of Medical Sciences

Saba.rezazadeh9294@gmail.com+98 45 3336 9847

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026